Status: Recruiting
A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
Participants needed: 112
Trial details
Phase: Phase 1Age: 18-50Biological sex: AllType: InterventionalSponsor: International AIDS Vaccine InitiativeUpdated: Apr 15, 2026Locations: 2
Eligibility criteria
Adults in good general health [+7]
Any clinically significant acute or chronic medical condition that is considered... [+15]